Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7
Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7
Rodman & Renshaw發起對trevi therapeutics的買入評級，宣佈目標價爲7美元。
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.
羅德曼與倫肖分析師Brandon Folkes爲Trevi Therapeutics（納斯達克：TRVI）授予買入評級並公佈7美元的目標價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。